Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2019 Aug 10

PMID 31394725

Citations 113

Authors

Mateo Cortes Rivera

Claudio Mastronardi

Claudia T Silva-Aldana

Mauricio Arcos-Burgos

Brett A Lidbury

Affiliations

Soon will be listed here.

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease of unknown aetiology that is recognized by the World Health Organization (WHO) and the United States Center for Disease Control and Prevention (US CDC) as a disorder of the brain. The disease predominantly affects adults, with a peak age of onset of between 20 and 45 years with a female to male ratio of 3:1. Although the clinical features of the disease have been well established within diagnostic criteria, the diagnosis of ME/CFS is still of exclusion, meaning that other medical conditions must be ruled out. The pathophysiological mechanisms are unclear but the neuro-immuno-endocrinological pattern of CFS patients gleaned from various studies indicates that these three pillars may be the key point to understand the complexity of the disease. At the moment, there are no specific pharmacological therapies to treat the disease, but several studies' aims and therapeutic approaches have been described in order to benefit patients' prognosis, symptomatology relief, and the recovery of pre-existing function. This review presents a pathophysiological approach to understanding the essential concepts of ME/CFS, with an emphasis on the population, clinical, and genetic concepts associated with ME/CFS.

Citing Articles

mTORC1 syndrome (TorS): unifying paradigm for PASC, ME/CFS and PAIS.

Bar-Tana J J Transl Med. 2025; 23(1):297.

PMID: 40059164 PMC: 11892318. DOI: 10.1186/s12967-025-06220-z.

A network medicine approach to investigating ME/CFS pathogenesis in severely ill patients: a pilot study.

Hung L, Wu C, Chang C, Li P, Hicks K, Dibble J Front Hum Neurosci. 2025; 19:1509346.

PMID: 39996021 PMC: 11847890. DOI: 10.3389/fnhum.2025.1509346.

Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systematic Review.

Dorczok M, Mittmann G, Mossaheb N, Schrank B, Bartova L, Neumann M Nutrients. 2025; 17(3).

PMID: 39940333 PMC: 11819863. DOI: 10.3390/nu17030475.

The search for a blood-based biomarker for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS): from biochemistry to electrophysiology.

Clarke K, Kingdon C, Hughes M, Lacerda E, Lewis R, Kruchek E J Transl Med. 2025; 23(1):149.

PMID: 39905423 PMC: 11792299. DOI: 10.1186/s12967-025-06146-6.

Machine learning and multi-omics in precision medicine for ME/CFS.

Huang K, Lidbury B, Thomas N, Gooley P, Armstrong C J Transl Med. 2025; 23(1):68.

PMID: 39810236 PMC: 11731168. DOI: 10.1186/s12967-024-05915-z.

References

Jason L, Corradi K, Torres-Harding S, Taylor R, King C . Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev. 2005; 15(1):29-58. DOI: 10.1007/s11065-005-3588-2. View

Whistler T, Unger E, Nisenbaum R, Vernon S . Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome. J Transl Med. 2003; 1(1):10. PMC: 305360. DOI: 10.1186/1479-5876-1-10. View

Falkenberg V, Whistler T, Murray J, Unger E, Rajeevan M . Acute psychosocial stress-mediated changes in the expression and methylation of perforin in chronic fatigue syndrome. Genet Epigenet. 2014; 5:1-9. PMC: 4222335. DOI: 10.4137/GEG.S10944. View

Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M . Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS One. 2018; 13(3):e0193672. PMC: 5854315. DOI: 10.1371/journal.pone.0193672. View

Lattie E, Antoni M, Fletcher M, Penedo F, Czaja S, Lopez C . Stress management skills, neuroimmune processes and fatigue levels in persons with chronic fatigue syndrome. Brain Behav Immun. 2012; 26(6):849-58. PMC: 3572196. DOI: 10.1016/j.bbi.2012.02.008. View

Corbitt M, Campagnolo N, Staines D, Marshall-Gradisnik S . A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). Probiotics Antimicrob Proteins. 2018; 10(3):466-477. DOI: 10.1007/s12602-018-9397-8. View

Yamashita M, Yamamoto T . Tryptophan circuit in fatigue: From blood to brain and cognition. Brain Res. 2017; 1675:116-126. DOI: 10.1016/j.brainres.2017.09.002. View

Ren K, Dubner R . Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol. 2008; 21(5):570-9. PMC: 2735048. DOI: 10.1097/ACO.0b013e32830edbdf. View

Ricci G, Volpi L, Pasquali L, Petrozzi L, Siciliano G . Astrocyte-neuron interactions in neurological disorders. J Biol Phys. 2009; 35(4):317-36. PMC: 2750745. DOI: 10.1007/s10867-009-9157-9. View

10.

Slomko J, Newton J, Kujawski S, Tafil-Klawe M, Klawe J, Staines D . Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study. BMJ Open. 2019; 9(3):e023955. PMC: 6429942. DOI: 10.1136/bmjopen-2018-023955. View

11.

Mensah F, Bansal A, Berkovitz S, Sharma A, Reddy V, Leandro M . Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study. Clin Exp Immunol. 2015; 184(2):237-47. PMC: 4837232. DOI: 10.1111/cei.12749. View

12.

Comhaire F . Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial. Med Hypotheses. 2018; 114:45-48. DOI: 10.1016/j.mehy.2018.03.002. View

13.

Garcia-Ortega M, Lopez G, Jimenez G, Garcia-Garcia J, Conde V, Boulaiz H . Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism. Expert Rev Mol Med. 2017; 19:e9. DOI: 10.1017/erm.2017.11. View

14.

Petty R, McCarthy N, Le Dieu R, Kerr J . MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer (NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME). PLoS One. 2016; 11(3):e0150904. PMC: 4788442. DOI: 10.1371/journal.pone.0150904. View

15.

Hulsebosch C . Gliopathy ensures persistent inflammation and chronic pain after spinal cord injury. Exp Neurol. 2008; 214(1):6-9. PMC: 2888707. DOI: 10.1016/j.expneurol.2008.07.016. View

16.

Peterson P, Pheley A, Schroeppel J, Schenck C, Marshall P, Kind A . A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med. 1998; 158(8):908-14. DOI: 10.1001/archinte.158.8.908. View

17.

McKenzie R, OFallon A, Dale J, Demitrack M, Sharma G, Deloria M . Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA. 1998; 280(12):1061-6. DOI: 10.1001/jama.280.12.1061. View

18.

Rajeevan M, Dimulescu I, Murray J, Falkenberg V, Unger E . Pathway-focused genetic evaluation of immune and inflammation related genes with chronic fatigue syndrome. Hum Immunol. 2015; 76(8):553-60. DOI: 10.1016/j.humimm.2015.06.014. View

19.

Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S . Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. 2016; 187(2):284-293. PMC: 5217865. DOI: 10.1111/cei.12882. View

20.

Tomas C, Newton J, Watson S . A review of hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. ISRN Neurosci. 2014; 2013:784520. PMC: 4045534. DOI: 10.1155/2013/784520. View